FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication

On March 28, 2025, the Food and Drug Administration expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation). Learn more.